Baird analyst David Rescott lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $90 and keeps a Neutral rating on the shares. The firm updated its model following results hich showed double digit top line growth but the visibility and valuation keeps them on the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs
- Edwards Lifesciences price target raised to $100 from $98 at Piper Sandler
- AtriCure downgraded to Neutral from Overweight at JPMorgan
- Closing Bell Movers: Robinhood slips 8% after revenue miss
- Edwards Lifesciences reports Q4 adjusted EPS 58c, consensus 62c